Title: Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Journal: Mini reviews in medicinal chemistry20121101
Title: Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Journal: Journal of clinical pharmacology20121001
Title: Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Journal: Diabetes, obesity & metabolism20121001
Title: Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Journal: American journal of physiology. Renal physiology20121001
Title: Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Journal: Cardiovascular research20121001
Title: Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
Journal: Bioorganic & medicinal chemistry20121001
Title: Linagliptin as add-on therapy for type 2 diabetes - an overview.
Journal: Drugs of today (Barcelona, Spain : 1998)20121001
Title: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
Journal: Clinical pharmacokinetics20120801
Title: Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Journal: Endocrine20120601
Title: Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
Journal: European journal of medicinal chemistry20120601
Title: Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
Journal: The Journal of clinical endocrinology and metabolism20120501
Title: An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Journal: Current diabetes reviews20120501
Title: DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Journal: Diabetes & metabolism20120401
Title: Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Journal: Diabetologia20120401
Title: Alogliptin benzoate for the treatment of type 2 diabetes.
Journal: Expert opinion on pharmacotherapy20120301
Title: Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
Journal: The Annals of pharmacotherapy20120301
Title: Pleiotropic effects of incretins.
Journal: Indian journal of endocrinology and metabolism20120301
Title: A review of gliptins in 2011.
Journal: Expert opinion on pharmacotherapy20120101
Title: DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Journal: Advances in therapy20120101
Title: Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Journal: Cardiovascular diabetology20120101
Title: Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.
Journal: ISRN endocrinology20120101
Title: Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20120101
Title: Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20120101
Title: Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Journal: Current medicinal chemistry20120101
Title: Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Journal: Diabetes, obesity & metabolism20111201
Title: Impact of diabetes on postinfarction heart failure and left ventricular remodeling.
Journal: Current heart failure reports20111201
Title: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Journal: Circulation20111122
Title: Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Journal: Diabetes, obesity & metabolism20111101
Title: Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
Journal: Clinical therapeutics20111101
Title: Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Journal: Current medical research and opinion20111101
Title: Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Journal: Current medical research and opinion20111101
Title: EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
Journal: American heart journal20111001
Title: 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): a potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A.
Journal: Bioorganic & medicinal chemistry20110915
Title: Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Journal: Current medical research and opinion20110901
Title: Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Journal: Recent patents on endocrine, metabolic & immune drug discovery20110901
Title: Emerging role of insulin with incretin therapies for management of type 2 diabetes.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders20110901
Title: DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Journal: Journal of cardiovascular pharmacology20110801
Title: [The expectation for DPP-4 inhibitors on future treatment of type 2 diabetes mellitus].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110801
Title: Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.
Journal: Diabetes & metabolism journal20110801
Title: Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview.
Journal: Expert opinion on drug discovery20110801
Title: Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Journal: Drugs20110730
Title: Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Journal: Diabetes, obesity & metabolism20110701
Title: Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Journal: Expert opinion on investigational drugs20110601
Title: An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Journal: Contemporary clinical trials20110501
Title: [Alogliptin].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110501
Title: [A compounding agent of alogliptin and pioglitazone].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110501
Title: [Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110501
Title: Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Journal: Clinical therapeutics20110501
Title: Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.
Journal: Diabetes, obesity & metabolism20110401
Title: Alogliptin for the treatment of type 2 diabetes.
Journal: Drugs of today (Barcelona, Spain : 1998)20110201
Title: Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Journal: Hospital practice (1995)20110201
Title: Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Journal: Journal of medicinal chemistry20110127
Title: Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice.
Journal: Biochemical and biophysical research communications20110107
Title: The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Journal: European journal of medicinal chemistry20110101
Title: [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica20110101
Title: Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.
Journal: Vascular pharmacology20110101
Title: Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.
Journal: Journal of medical case reports20110101
Title: Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.
Journal: PloS one20110101
Title: Effective therapy using voglibose for nonalcoholic steatohepatitis in a patient with insufficient dietary and exercise therapy: exploring other treatment possibilities.
Journal: Case reports in gastroenterology20110101
Title: From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.
Journal: Experimental diabetes research20110101
Title: Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications.
Journal: Experimental diabetes research20110101
Title: Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Journal: The open medicinal chemistry journal20110101
Title: Choosing a gliptin.
Journal: Indian journal of endocrinology and metabolism20110101
Title: Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Journal: PloS one20110101
Title: A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Journal: Cardiovascular diabetology20110101
Title: Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Journal: Experimental diabetes research20110101
Title: DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.
Journal: Atherosclerosis20101201
Title: Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.
Journal: Korean diabetes journal20101201
Title: DPP-4 inhibitors: what may be the clinical differentiators?
Journal: Diabetes research and clinical practice20101101
Title: Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Journal: Diabetes care20101101
Title: Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.
Journal: Current diabetes reviews20101101
Title: Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Journal: Drugs20101022
Title: Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
Journal: The American journal of geriatric pharmacotherapy20101001
Title: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Journal: Clinical pharmacokinetics20100901
Title: Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Journal: The American journal of the medical sciences20100801
Title: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Journal: Diabetes, obesity & metabolism20100801
Title: Recommendations for management of diabetes during Ramadan: update 2010.
Journal: Diabetes care20100801
Title: The evolving place of incretin-based therapies in type 2 diabetes.
Journal: Pediatric nephrology (Berlin, Germany)20100701
Title: Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Journal: Diabetes, obesity & metabolism20100301
Title: The physiologic role of incretin hormones: clinical applications.
Journal: The Journal of the American Osteopathic Association20100301
Title: Incretin concepts.
Journal: Diabetes care20100201
Title: Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Journal: International journal of clinical pharmacology and therapeutics20100101
Title: The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
Journal: Diabetes technology & therapeutics20100101
Title: Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk.
Journal: Vascular health and risk management20100101
Title: Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Journal: Mediators of inflammation20100101
Title: Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.
Journal: Beilstein journal of organic chemistry20100101
Title: Exenatide once weekly: clinical outcomes and patient satisfaction.
Journal: Patient preference and adherence20100101
Title: Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Journal: Vascular health and risk management20100101
Title: Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101
Title: New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101
Title: Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20100101
Title: Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
Journal: Drug, healthcare and patient safety20100101
Title: Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
Journal: Diabetes, obesity & metabolism20091201
Title: Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Journal: Journal of the American Geriatrics Society20091101
Title: Incretin-based therapies: viewpoints on the way to consensus.
Journal: Diabetes care20091101
Title: Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes.
Journal: Expert review of clinical pharmacology20091101
Title: Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Journal: Journal of clinical pharmacology20091001
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Journal: Current medical research and opinion20091001
Title: Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Journal: Clinical science (London, England : 1979)20090928
Title: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Journal: Diabetes care20090901
Title: Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
Journal: European journal of medicinal chemistry20090801
Title: A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Journal: Life sciences20090717
Title: Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Journal: British journal of pharmacology20090601
Title: Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Journal: The Journal of pharmacology and experimental therapeutics20090501
Title: Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry20090301
Title: Diabetes treatment.
Journal: Diabetes care20090301
Title: DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Journal: Advances in therapy20090301
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Journal: Diabetes, obesity & metabolism20090201
Title: Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Journal: Expert opinion on pharmacotherapy20090201
Title: The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Journal: European journal of pharmacology20090114
Title: Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Journal: International journal of clinical practice20090101
Title: Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice.
Journal: Postgraduate medicine20090101
Title: A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.
Journal: Cardiovascular diabetology20090101
Title: Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.
Journal: Therapeutics and clinical risk management20090101
Title: New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
Journal: The Diabetes educator20090101
Title: Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Journal: Journal of the American Pharmacists Association : JAPhA20090101
Title: Efficacy and safety of incretin based therapies: clinical trial data.
Journal: Journal of the American Pharmacists Association : JAPhA20090101
Title: Alogliptin: a new addition to the class of DPP-4 inhibitors.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy20090101
Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Journal: Diabetes care20081201
Title: Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Journal: Expert opinion on emerging drugs20081201
Title: Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Journal: European journal of pharmacology20080728
Title: Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Journal: European journal of pharmacology20080707
Title: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Journal: The Journal of pharmacology and experimental therapeutics20080401
Title: Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Journal: Current opinion in investigational drugs (London, England : 2000)20080401
Title: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Journal: Clinical therapeutics20080301
Title: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Journal: Clinical therapeutics20080301
Title: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
Journal: BMC endocrine disorders20080101
Title: Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Journal: Current topics in medicinal chemistry20080101
Title: Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Journal: Journal of medicinal chemistry20070517
Title: Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300.
Title: Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35.
Title: Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187.
Title: Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6.
Title: Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54.
